相关实验视频

Updated: May 5, 2026

Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots

Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots

Published on: May 21, 2017

在胸腔外科医生协会数据库中的生物假体与机械大动脉置换中的再手术

Tsuyoshi Kaneko¹, Shinichi Fukuhara², J Hunter Mehaffey³

¹Division of Cardiothoracic Surgery, Washington University in St Louis, St Louis, Missouri.

The Annals of thoracic surgery

|October 29, 2025

概括

对于63岁或以下的患者,机械大动脉置换 (AVR) 显示了较低的重复手术和死亡风险. 对于老年患者来说,生物假体AVR提供了优异的结果,为共享的临床决策提供了信息.

科学领域:

心血管外科心血管外科
生物材料科学生物材料科学
健康结果研究研究结果

背景情况:

在生物假肢和机械大动脉置换 (AVR) 之间做出选择需要平衡门的耐用性,患者的寿命和重新干预的需要.
在临床实践中,AVR再操作和生存的当代,现实,长期结果至关重要.
胸腔外科医生协会成人心脏手术数据库为评估这些结果提供了一个强大的平台.

研究的目的:

评估大动脉置换 (AVR) 重新操作和生存的当代,现实,长期结果.
在不同年龄组的患者中,比较生物假肢与机械AVR的性能.
为了为临床决策提供有关假肢大动脉选择的信息.

主要方法:

从胸部外科医生协会数据库 (2008-2019) 中对初级隔离生物假体或机械AVR患者的分析.
排除高风险患者 (例如,年龄超过80岁,内心炎,休克,之前的手术).
风险调整使用逆概率加权和限制的立方线对年龄相关结果和通过国家死亡指数的死亡率联系进行风险调整.

主要成果:

140,516名患者接受了AVR (122,453名生物假体,18,063名机械).
机械AVR显示,在≤63岁的患者中,重新手术或全因死亡风险较低.
生物假体AVR在≥72岁的患者中表现出优异的结果,相当于63-72岁.

结论:

机械AVR与较低风险调整后的重新手术或所有原因的死亡率相关,患者年龄 ≤63岁.
基于当代的长期数据,对72岁以上的患者来说,生物假体AVR是最受欢迎的.
这些发现支持患者和提供者之间为最佳假体大动脉选择进行共享决策.

更多相关视频

Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement

Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement

Published on: December 11, 2017

Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model

Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model

Published on: June 8, 2022

相关概念视频

Mitral Stenosis III: Medical Management

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...

Aortic Regurgitation III: Medical Management

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...